RADIUS ANNOUNCES LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE EISAI SERMS

Radius announced today that it has acquired exclusive worldwide rights, excluding Japan, to a new class of selective estrogen receptor modulators (SERMs) discovered by Eisai Co., Ltd. Radius is currently advancing its first development candidate from this class, RAD 1901, into pre-IND studies for the treatment and prevention of hot flashes (vasomotor symptoms) and osteoporosis. Financial terms were not disclosed.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-29-2006/0004389454&EDATE=)